ALM 401
Alternative Names: EGFRXROR1 bispecifiic ADC; ALM-401; TSY-310Latest Information Update: 30 Jul 2026
At a glance
- Originator Almac Discovery
- Class Antineoplastics; Auristatins; Bispecific antibodies; Drug conjugates; Immunotoxins
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jun 2026 Pharmacodynamics data from a preclinical study in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 06 May 2025 ALM 401 licensed to Formosa Pharmaceuticals in world
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)